A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity

  • Grabiner B
  • Nardi V
  • Birsoy K
 et al. 
  • 153

    Readers

    Mendeley users who have this article in their library.
  • 117

    Citations

    Citations of this article.

Abstract

Genes encoding components of the PI3K-AKT-mTOR signaling axis are frequently mutated in cancer, but few mutations have been characterized in MTOR, the gene encoding the mTOR kinase. Using publicly available tumor genome sequencing data, we generated a comprehensive catalog of mTOR pathway mutations in cancer, identifying 33 MTOR mutations that confer pathway hyperactivation. The mutations cluster in six distinct regions in the C-terminal half of mTOR and occur in multiple cancer types, with one cluster particularly prominent in kidney cancer. The activating mutations do not affect mTOR complex assembly, but a subset reduces binding to the mTOR inhibitor DEPTOR. mTOR complex 1 (mTORC1) signaling in cells expressing various activating mutations remains sensitive to pharmacologic mTOR inhibition, but is partially resistant to nutrient deprivation. Finally, cancer cell lines with hyperactivating MTOR mutations display heightened sensitivity to rapamycin both in culture and in vivo xenografts, suggesting that such mutations confer mTOR pathway dependency.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Brian C. Grabiner

  • Valentina Nardi

  • Kivanç Birsoy

  • Richard Possemato

  • Kuang Shen

  • Sumi Sinha

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free